Key Points
- Insider sale: William Jacob Savage sold 5,731 shares on April 13 at $66.38 for $380,423.78, cutting his stake by 6.73% to 79,480 shares (worth about $5.28M).
- Savage has executed multiple sales this year (Feb. 17, Mar. 2 and Apr. 13), totaling roughly $1.07 million, indicating a pattern of insider selling over recent months.
- Market context: IRON trades near $70.18 with a 50-day/200-day moving average of $64.76/$76.14, a market cap of $2.68B, and a consensus analyst rating of Moderate Buy with an average target of $104.80.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean Franchi sold 400 shares of the business's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $69.00, for a total value of $27,600.00. Following the completion of the transaction, the chief financial officer owned 70,590 shares of the company's stock, valued at $4,870,710. This trade represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Disc Medicine Trading Down 0.4%
Shares of IRON opened at $70.18 on Thursday. The stock has a fifty day moving average of $64.76 and a two-hundred day moving average of $76.14. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94. The company has a market capitalization of $2.68 billion, a PE ratio of -11.72 and a beta of 0.91. Disc Medicine, Inc. has a fifty-two week low of $39.20 and a fifty-two week high of $99.50.
Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. As a group, analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.
Institutional Trading of Disc Medicine
Several institutional investors have recently made changes to their positions in IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock valued at $756,000 after buying an additional 2,807 shares during the period. Millennium Management LLC grew its stake in shares of Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company's stock valued at $5,386,000 after buying an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Disc Medicine by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock valued at $4,793,000 after buying an additional 3,454 shares during the period. Legal & General Group Plc grew its stake in shares of Disc Medicine by 18.0% during the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company's stock valued at $1,276,000 after buying an additional 3,682 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Disc Medicine by 21.6% during the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company's stock valued at $891,000 after buying an additional 2,983 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts have weighed in on IRON shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Disc Medicine in a report on Wednesday, January 21st. Wedbush cut their price target on Disc Medicine from $110.00 to $88.00 and set an "outperform" rating for the company in a report on Tuesday, February 17th. Stifel Nicolaus cut their price target on Disc Medicine from $125.00 to $110.00 and set a "buy" rating for the company in a report on Tuesday, February 17th. Wells Fargo & Company boosted their price target on Disc Medicine from $78.00 to $79.00 and gave the company an "overweight" rating in a report on Monday, March 2nd. Finally, TD Cowen reissued a "buy" rating on shares of Disc Medicine in a research note on Friday, December 19th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Disc Medicine presently has an average rating of "Moderate Buy" and an average target price of $104.80.
Read Our Latest Stock Report on IRON
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
